Novo Nordisk's Wegovy Pill Wins EU Approval, Beating Lilly's Foundayo to Market
LLY sits 83% above its 52-week low of $623.78 on light trading volume (0.3× avg).
Summary
Novo Nordisk secured EU approval for its oral Wegovy pill, the first oral GLP-1 weight-loss treatment cleared in Europe. This gives Novo a head start over Eli Lilly's Foundayo, which is still navigating the EU regulatory pathway. The approval covers adults with obesity or overweight with comorbidities, based on 17% average weight loss in trials. For Lilly, this intensifies competitive pressure in the lucrative European obesity market, where its injectable drugs already compete. The news follows recent positive data for Lilly's own oral candidate, but Novo's first-mover advantage could shift market share dynamics.
At the time of this announcement, LLY was trading at $1,141.73 on NYSE in the Life Sciences sector, with a market capitalization of approximately $1.1T. The 52-week trading range was $623.78 to $1,249.45. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.